MedTrace Logo

Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT04754035 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-10-03

No results posted yet for this study

Summary

This is a Phase 2a, multicenter, open-label uncontrolled study aimed at determining therapeutic benefits of the addition of ibrutinib to venetoclax in patients with relapsed/refractory CLL based on a MRD-guided approach.

Conditions

Interventions

DRUG

Venetoclax

venetoclax 20 mg, 50 mg, 100 mg

DRUG

Imbruvica Oral Product

Imbruvica 140 mg

Sponsors & Collaborators

  • Paolo Ghia

    lead OTHER

Principal Investigators

  • Paolo Ghia, Prof · San Raffaele Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2018-07-31
Completion
2025-09-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04754035 on ClinicalTrials.gov